# NfκBin: a machine learning based method for screening TNF-α induced NF-κB inhibitors

**Authors:** Shipra Jain, Ritu Tomer, Sumeet Patiyal, Gajendra P. S. Raghava

PMC · DOI: 10.3389/fbinf.2025.1573744 · Frontiers in Bioinformatics · 2025-07-17

## TL;DR

This paper introduces NfκBin, a machine learning tool to identify drugs that inhibit NF-κB signaling, a key pathway in inflammation-related diseases.

## Contribution

The novel contribution is a machine learning-based method for screening FDA-approved drugs as potential NF-κB inhibitors.

## Key findings

- A machine learning model achieved an AUC of 0.75 in predicting NF-κB inhibitors.
- The model successfully identified drugs previously validated as inhibitors in experimental studies.
- NfκBin is available as a web server and standalone software for drug screening.

## Abstract

Nuclear Factor kappa B (NF-κB) is a transcription factor whose upregulation is associated in chronic inflammatory diseases, including rheumatoid arthritis, inflammatory bowel disease, and asthma. In order to develop therapeutic strategies targeting NF-κB-related diseases, we developed a computational approach to predict drugs capable of inhibiting TNF-α induced NF-κB signaling pathways.

We utilized a dataset comprising 1,149 inhibitors and 1,332 non-inhibitors retrieved from PubChem. Chemical descriptors were computed using the PaDEL software, and relevant features were selected using advanced feature selection techniques.

Initially, machine learning models were constructed using 2D descriptors, 3D descriptors, and molecular fingerprints, achieving maximum AUC values of 0.66, 0.56, and 0.66, respectively. To improve feature selection, we applied univariate analysis and SVC-L1 regularization to identify features that can effectively differentiate inhibitors from non-inhibitors. Using these selected features, we developed machine learning models, our support vector classifier achieved a highest AUC of 0.75 on the validation dataset.

Finally, this best-performing model was employed to screen FDA-approved drugs for potential NF-κB inhibitors. Notably, most of the predicted inhibitors corresponded to drugs previously identified as inhibitors in experimental studies, underscoring the model’s predictive reliability. Our best-performing models have been integrated into a standalone software and web server, NfκBin. (https://webs.iiitd.edu.in/raghava/nfkbin/).

## Linked entities

- **Proteins:** NFKB1 (nuclear factor kappa B subunit 1), TNF (tumor necrosis factor)
- **Diseases:** rheumatoid arthritis (MONDO:0008383), inflammatory bowel disease (MONDO:0005265), asthma (MONDO:0004979)

## Full-text entities

- **Genes:** RCN1 (reticulocalbin 1) [NCBI Gene 5954] {aka HEL-S-84, PIG20, RCAL, RCN}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, MAP3K14 (mitogen-activated protein kinase kinase kinase 14) [NCBI Gene 9020] {aka FTDCR1B, HS, HSNIK, IMD112, NIK}, EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}, RELB (RELB proto-oncogene, NF-kB subunit) [NCBI Gene 5971] {aka I-REL, IMD53, IREL, REL-B}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, RCOR1 (REST corepressor 1) [NCBI Gene 23186] {aka COREST, RCOR}, TNFSF13B (TNF superfamily member 13b) [NCBI Gene 10673] {aka BAFF, BLYS, CD257, TALL-1, TALL1, THANK}, KCTD1 (potassium channel tetramerization domain containing 1) [NCBI Gene 284252] {aka C18orf5, DNRD, RMDA}, Nfkb1 (nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105) [NCBI Gene 18033] {aka NF-KB1, NF-kappaB, NF-kappaB1, p105, p50, p50/p105}, CD40 (CD40 molecule) [NCBI Gene 958] {aka Bp50, CDW40, TNFRSF5, p50}, LINC-ROR (long intergenic non-protein coding RNA, regulator of reprogramming) [NCBI Gene 100885779] {aka ROR, lincRNA-RoR, lincRNA-ST8SIA3}, NFKB2 (nuclear factor kappa B subunit 2) [NCBI Gene 4791] {aka CVID10, H2TF1, LYT-10, LYT10, NF-kB2, p100}, IL1A (interleukin 1 alpha) [NCBI Gene 3552] {aka IL-1 alpha, IL-1A, IL1, IL1-ALPHA, IL1F1}, MCC (MCC regulator of Wnt signaling pathway) [NCBI Gene 4163] {aka MCC1}, NLRP4 (NLR family pyrin domain containing 4) [NCBI Gene 147945] {aka CLR19.5, CT58, NALP4, PAN2, PYPAF4, RNH2}
- **Diseases:** metastasis (MESH:D009362), diseases (MESH:D004194), SVC (MESH:D000079426), bowel disease (MESH:D015212), immune disorders (MESH:D007154), SLE (MESH:D008180), inflammation (MESH:D007249), Crohn's disease (MESH:D003424), cancer (MESH:D009369), autoimmune disorders (MESH:D001327), rheumatoid arthritis (MESH:D001172), arthritis (MESH:D001168), asthma (MESH:D001249), multiple sclerosis (MESH:D009103), psoriasis (MESH:D011565), breast, lung, and colorectal cancers (MESH:D001943), toxicity (MESH:D064420)
- **Chemicals:** Alcohol (MESH:D000438), Ketone (MESH:D007659), Aldehyde (MESH:D000447), DMSO (MESH:D004121), Alkyne (MESH:D000480), Guanidine (MESH:D019791), Gentamicin (MESH:D005839), Bleomycin (MESH:D001761), Ester (MESH:D004952), Nitroprusside (MESH:D009599), Phosphates (MESH:D010710), Pentosan polysulfate (MESH:D010426), Carboxylic Acid (MESH:D002264), Ether (MESH:D004986), NO (MESH:D009614), Amines (MESH:D000588), Nitrile (MESH:D009570), Tobramycin (MESH:D014031), R2NH (-), Ivermectin (MESH:D007559)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** 293T — Homo sapiens (Human), Transformed cell line (CVCL_0063)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12310657/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12310657/full.md

## References

58 references — full list in the complete paper: https://tomesphere.com/paper/PMC12310657/full.md

---
Source: https://tomesphere.com/paper/PMC12310657